852 related articles for article (PubMed ID: 30344420)
1. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
2. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.
Kreisel W; Lazaro A; Trebicka J; Grosse Perdekamp M; Schmitt-Graeff A; Deibert P
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638713
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.
Kreisel W; Schaffner D; Lazaro A; Trebicka J; Merfort I; Schmitt-Graeff A; Deibert P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872119
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.
Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW
Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203
[TBL] [Abstract][Full Text] [Related]
6. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers.
Loureiro-Silva MR; Iwakiri Y; Abraldes JG; Haq O; Groszmann RJ
J Hepatol; 2006 May; 44(5):886-93. PubMed ID: 16545481
[TBL] [Abstract][Full Text] [Related]
7. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats.
Morales-Ruiz M; Cejudo-Martín P; Fernández-Varo G; Tugues S; Ros J; Angeli P; Rivera F; Arroyo V; Rodés J; Sessa WC; Jiménez W
Gastroenterology; 2003 Aug; 125(2):522-31. PubMed ID: 12891555
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
9. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
10. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
11. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.
Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096
[TBL] [Abstract][Full Text] [Related]
12. Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity.
Hu H; Zharikov S; Patel JM
Peptides; 2012 May; 35(1):78-85. PubMed ID: 22465621
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.
Liang J; Deng X; Lin ZX; Zhao LC; Zhang XL
World J Gastroenterol; 2009 Sep; 15(36):4529-37. PubMed ID: 19777611
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension.
Yu Q; Shao R; Qian HS; George SE; Rockey DC
J Clin Invest; 2000 Mar; 105(6):741-8. PubMed ID: 10727442
[TBL] [Abstract][Full Text] [Related]
15. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
16. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
[TBL] [Abstract][Full Text] [Related]
17. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
[TBL] [Abstract][Full Text] [Related]
18. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
Lan TH; Chen XL; Wu YS; Qiu HL; Li JZ; Ruan XM; Xu DP; Lin DQ
Eur J Pharmacol; 2018 Jun; 829():102-111. PubMed ID: 29665366
[TBL] [Abstract][Full Text] [Related]
19. Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.
Jones AK; Chen H; Ng KJ; Villalona J; McHugh M; Zeveleva S; Wilks J; Brilisauer K; Bretschneider T; Qian HS; Fryer RM
J Pharmacol Exp Ther; 2023 Jul; 386(1):70-79. PubMed ID: 37230799
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Andric SA; Janjic MM; Stojkov NJ; Kostic TS
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
